Table 2 Association between demographic characteristics, PFS and OS (N = 429).

From: Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Characteristics

PFS

OS

   

Univariate

Multivariate

 

Univariate

 

Multivariate

 

N

Median (months) (95% CI)

HR (95% CI)

P-value

HR (95% CI)

P-value

Median (months) (95% CI)

HR (95% CI)

P-value

HR (95% CI)

P-value

Age, years

≥61

220

4.00 (2.98–5.02)

0.89 (0.73–1.10)

0.273

—

—

10.00 (7.61–12.39)

1.06 (0.83–1.36)

0.618

—

—

<61

209

4.00 (3.37–4.63)

—

—

—

—

12.00 (10.13–13.87)

—

—

—

—

Sex

Male

167

3.00 (2.30–3.70)

1.12 (0.91–1.39)

0.288

—

—

9.00 (6.13–11.88)

1.16 (0.91–1.49)

0.233

—

—

Female

262

5.00 (4.32–5.68)

—

—

—

—

12.00 (10.46–13.54)

—

—

—

—

Matching score (%)

≥50%

125

6.00 (4.27–7.73)

0.63 (0.50–0.80)

< 0.001

0.62 (0.47–0.81)

0.001

17.00 (9.73–24.27)

0.67 (0.50–0.89)

0.006

0.67 (0.50–0.90)

0.007

<50%

304

4.00 (3.52–4.49)

—

—

—

—

10.00 (8.34–11.66)

—

—

—

—

GI malignanciesa

Yes

123

4.00 (3.23–4.77)

1.11 (0.88–1.39)

0.381

—

—

8.00 (5.58–10.42)

1.32 (1.01–1.72)

0.041

1.32 (1.01–1.72)

0.044

No

306

4.00 (3.19–4.81)

—

—

—

—

12.00 (10.13–13.87)

—

—

—

—

Number of prior lines of therapy

≥3

204

4.00 (3.45–4.55)

1.28 (1.04–1.57)

0.021

1.27 (1.03–1.57)

0.023

9.00 (6.47–11.53)

1.48 (1.16–1.88)

0.002

1.49 (1.16–1.90)

0.001

<3

225

5.00 (4.09–5.91)

—

—

—

—

13.00 (8.15–17.85)

—

—

—

—

Immunotherapy-based regimenb

Yes

80

5.00 (2.49–7.51)

0.79 (0.60–1.04)

0.098

1.04 (0.76–1.42)

0.829

13.00 (6.12–19.89)

0.93 (0.67–1.29)

0.651

—

—

No

349

4.00 (3.35–4.65)

—

—

—

—

11.00 (9.25–12.75)

—

—

—

—

  1. aAmong 123 patients with heterogeneous GI malignancies, matching score of ≥50% (N = 33) vs. <50% (N = 90) showed significant difference in PFS (HR: 0.62, 95% CI: 0.39–0.98, P = 0.042). However, there was no difference in OS (HR: 0.74, 95% CI: 0.43–1.27, P = 0.268.
  2. bSixty of the 80 patients receiving immunotherapy were matched based on profiling.
  3. CI confidence interval, HR hazard ratio, GI gastrointestinal, OS overall survival, PFS progression-free survival.
Back to article page